Safety and Efficacy of Renin–Angiotensin–Aldosterone System Inhibitors in COVID-19 Population

INTRODUCTION: The safety of renin–angiotensin–aldosterone system inhibitors (RAASi) among COVID-19 patients has been controversial since the onset of the pandemic. METHODS: Digital databases were queried to study the safety of RAASi in COVID-19. The primary outcome of interest was mortality. The sec...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:High Blood Press Cardiovasc Prev
Autores principales: Sattar, Yasar, Mukuntharaj, Pradeeksha, Zghouzi, Mohamed, Suleiman, Abdul-Rahman M., Attique, Hassan, Ullah, Waqas, Sana, Muhammad Khawar, Zaher, Nathan, Mehmood, Maham, Doshi, Rajkumar P., Panchal, Ankur, Mir, Tanveer, Nadeem, Muhammad, Ali, Omar E., Mohamed, Mohamad, Bagur, Rodrigo, Elgendy, Islam Y., Mamas, Mamas A., Alraies, M. Chadi
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer International Publishing 2021
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8237039/
https://ncbi.nlm.nih.gov/pubmed/34181203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40292-021-00462-w
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares